CD38

Chr 4

CD38 molecule

Also known as: ADPRC 1, ADPRC1, cADPR1

The protein encoded by this gene is a non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes cyclic adenosine 5'-diphosphate-ribose, an intracellular calcium ion mobilizing messenger. The release of soluble protein and the ability of membrane-bound protein to become internalized indicate both extracellular and intracellular functions for the protein. This protein has an N-terminal cytoplasmic tail, a single membrane-spanning domain, and a C-terminal extracellular region with four N-glycosylation sites. Crystal structure analysis demonstrates that the functional molecule is a dimer, with the central portion containing the catalytic site. It is used as a prognostic marker for patients with chronic lymphocytic leukemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]

GeneReviewsOMIMResearchGenerating clinical summary…
12
Active trials
1347
Pubs (1 yr)
P/LP submissions
P/LP missense
1.13
LOEUF
Multiple*
Mechanism· predicted
📖
GeneReview available — CD38
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.13LOEUF
pLI 0.000
Z-score 1.19
OE 0.68 (0.431.13)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
-0.06Z-score
OE missense 1.01 (0.891.15)
167 obs / 164.7 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?0.68 (0.431.13)
00.351.4
Missense OE?1.01 (0.891.15)
00.61.4
Synonymous OE?0.84
01.21.6
LoF obs/exp: 11 / 16.2Missense obs/exp: 167 / 164.7Syn Z: 0.96

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

CD38 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

AutophagyGalectinsHIV Infections

Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.

RECRUITING
NCT04160455Centre Hospitalier Régional d'OrléansStarted 2019-11-07
expression of a panel
HIVZinc StatusHIV Infection

Zn Supplementation in HIV Immunological Non Responders

RECRUITING
NCT06612554Phase NAParc de Salut MarStarted 2025-01-02
zinc acetatePlacebo
Acute Myeloid Leukemia

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

RECRUITING
NCT06880354Phase PHASE1Institute of Hematology & Blood Diseases Hospital, ChinaStarted 2025-05-22
CLL1 and CD38 Dual-Target CAR-T Cell Injection
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)

RECRUITING
NCT05071222Phase PHASE1, PHASE2Assistance Publique - Hôpitaux de ParisStarted 2023-07-19
ARTEGENE drug product
SepsisSeptic Shock

Myeloid Bias in the Bone Marrow of Septic Patients and Its Correlation With Disease Severity and Prognosis: A Single-Center, Prospective Cohort Study

NOT YET RECRUITING
NCT07667153Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyStarted 2026-07-15
Bone marrow aspirate collection
Multiple Myeloma

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

ACTIVE NOT RECRUITING
NCT06169215Phase PHASE2National Cancer Institute (NCI)Started 2024-07-23
Biospecimen CollectionBone Marrow AspirationBone Marrow Biopsy
HIV InfectionsAlcohol DrinkingAging

Precision Microbiota Interventions for Senoreduction Trial

NOT YET RECRUITING
NCT07462767Phase PHASE1, PHASE2Louisiana State University Health Sciences Center in New OrleansStarted 2026-04-01
Limosilactobacillus reuteriBlueberry extract
IgG4-related Disease

BCT301 in Treating Refractory/Recurrent IgG4-related Disease

NOT YET RECRUITING
NCT07793903Phase NAPeking University Third HospitalStarted 2026-10
BCT301 Cell Injection
Cavernous Malformation, Cerebral

Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study

NOT YET RECRUITING
NCT07026604Phase EARLY_PHASE1Beijing Tiantan HospitalStarted 2025-07-01
Daratumumab
Acute Myeloid Leukemia

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

NOT YET RECRUITING
NCT03222674Phase PHASE1, PHASE2Shenzhen Geno-Immune Medical InstituteStarted 2026-12-31
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
AstrocytomaGlioblastomaProgressive Disease

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

RECRUITING
NCT07560865Phase PHASE1Masonic Cancer Center, University of MinnesotaStarted 2026-04-23
FT536Biopsy/ Intratumoral Injection/ Gross Tumor ResectionBlood/ Cerebrospinal Fluid/ Tumor Pathology
Plasma Cell Myeloma

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

RECRUITING
NCT05561387Phase PHASE3SWOG Cancer Research NetworkStarted 2023-10-12
BortezomibDaratumumab and Hyaluronidase-fihjDexamethasone